Zoll Medical said today that it acquired TherOx and its acute myocardial infarction treatment.
TherOx’s SuperSaturated Oxygen Therapy system delivers a 60-minute infusion of the patient’s super-oxygenated blood to a targeted ischemic area of the heart via a small catheter. The treatment is designed to improve microvascular flow and reduce infarct size following primary coronary intervention with stenting.
“Zoll and TherOx are both focused on emergency cardiac care,” Neil Johnston, president of Zoll Circulation, said in prepared remarks. “This acquisition expands the Zoll product portfolio in support of excellence for patients and caregivers.”
“SSO2 Therapy can help reduce infarct size among patients who suffer from large anterior AMIs, which are the most serious heart attacks,” TherOx president & CEO Kevin Larkin added. “Adjunctive to PCI, SSO2 Therapy is intended to salvage heart muscle and reduce infarct size.”
“No delay in door-to-balloon times and improved clinical outcomes is a combination we think physicians will find appealing,” Johnston said. “Because SSO2 Therapy is delivered following PCI and stenting, there is no disruption of today’s workflow in the cath lab.”
The financial details of the acquisition were not disclosed. This is the second purchase made public by Zoll this month; last week, the company announced that it acquired Cardiac Science and its portfolio of automated external defibrillators.